Compile Data Set for Download or QSAR
Report error Found 91 for UniProtKB: P63165
TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621214(US20230303584, Compound 311)
Affinity DataIC50: 130nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621186(US20230303584, Compound 254)
Affinity DataIC50: 140nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621203(US20230303584, Compound 294)
Affinity DataIC50: 160nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621191(US20230303584, Compound 266)
Affinity DataIC50: 190nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621222(US20230303584, Compound 321)
Affinity DataIC50: 240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621200(US20230303584, Compound 285)
Affinity DataIC50: 240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621209(US20230303584, Compound 302)
Affinity DataIC50: 250nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621197(US20230303584, Compound 280)
Affinity DataIC50: 260nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621201(US20230303584, Compound 288)
Affinity DataIC50: 270nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621215(US20230303584, Compound 312)
Affinity DataIC50: 280nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621194(US20230303584, Compound 272)
Affinity DataIC50: 300nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621226(US20230303584, Compound 325)
Affinity DataIC50: 320nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621220(US20230303584, Compound 318)
Affinity DataIC50: 330nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621225(US20230303584, Compound 324)
Affinity DataIC50: 340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621223(US20230303584, Compound 322)
Affinity DataIC50: 340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621231(US20230303584, Compound 330)
Affinity DataIC50: 350nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621224(US20230303584, Compound 323)
Affinity DataIC50: 390nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621211(US20230303584, Compound 307)
Affinity DataIC50: 400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621196(US20230303584, Compound 279)
Affinity DataIC50: 400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621212(US20230303584, Compound 308)
Affinity DataIC50: 430nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621206(US20230303584, Compound 298)
Affinity DataIC50: 440nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621187(US20230303584, Compound 255)
Affinity DataIC50: 500nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621188(US20230303584, Compound 256)
Affinity DataIC50: 510nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621208(US20230303584, Compound 301)
Affinity DataIC50: 560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621217(US20230303584, Compound 314)
Affinity DataIC50: 560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621190(US20230303584, Compound 265)
Affinity DataIC50: 560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621229(US20230303584, Compound 328)
Affinity DataIC50: 580nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621219(US20230303584, Compound 317)
Affinity DataIC50: 620nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621189(US20230303584, Compound 264)
Affinity DataIC50: 640nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621234(US20230303584, Compound 336)
Affinity DataIC50: 650nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621230(US20230303584, Compound 329)
Affinity DataIC50: 720nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621193(US20230303584, Compound 271)
Affinity DataIC50: 770nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621228(US20230303584, Compound 327)
Affinity DataIC50: 850nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621199(US20230303584, Compound 284)
Affinity DataIC50: 860nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621227(US20230303584, Compound 326)
Affinity DataIC50: 870nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621240(US20230303584, Compound 353)
Affinity DataIC50: 890nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621192(US20230303584, Compound 267)
Affinity DataIC50: 900nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621210(US20230303584, Compound 304)
Affinity DataIC50: 900nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621221(US20230303584, Compound 319)
Affinity DataIC50: 930nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621233(US20230303584, Compound 335)
Affinity DataIC50: 940nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621241(US20230303584, Compound 354)
Affinity DataIC50: 960nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621195(US20230303584, Compound 277)
Affinity DataIC50: 1.10E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621205(US20230303584, Compound 297)
Affinity DataIC50: 1.40E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM103826(SPI-01 | US9791447, Compound SPI-01 | US11041859, ...)
Affinity DataIC50: 1.42E+3nMAssay Description:The inhibitors confer the non-competitive inhibitory mechanism, as shown by nuclear magnetic resonance (NMR) and quantitative enzyme kinetic analysis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621218(US20230303584, Compound 316)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621198(US20230303584, Compound 281)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621236(US20230303584, Compound 342)
Affinity DataIC50: 1.51E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621239(US20230303584, Compound 352)
Affinity DataIC50: 1.56E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM621237(US20230303584, Compound 343)
Affinity DataIC50: 1.58E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM103829(SPI-04 | US9791447, Compound SPI-04 | US11041859, ...)
Affinity DataIC50: 1.60E+3nMAssay Description:The inhibitors confer the non-competitive inhibitory mechanism, as shown by nuclear magnetic resonance (NMR) and quantitative enzyme kinetic analysis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 91 total ) | Next | Last >>
Jump to: